These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28716033)

  • 21. Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
    Saha A; Varughese M; Gallagher CJ; Orphanos G; Wilson P; Oram D; Jeyarajah A; Reynolds K; Shepherd J; McCormack M; Olaitan A; McDonald N; Mould T; McNeish I; Ledermann JA
    Int J Gynecol Cancer; 2012 May; 22(4):566-72. PubMed ID: 22426404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
    Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer.
    Derlatka P; Sienko J; Grabowska-Derlatka L; Palczewski P; Danska-Bidzinska A; Bidzinski M; Czajkowski K
    World J Surg Oncol; 2016 Feb; 14():58. PubMed ID: 26923029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
    Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index.
    Llueca A; Serra A; Rivadulla I; Gomez L; Escrig J;
    World J Surg Oncol; 2018 Feb; 16(1):37. PubMed ID: 29471831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy.
    Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G
    Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
    Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
    Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
    Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
    Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 May; 117(2):330-5. PubMed ID: 20189234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
    Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?
    Rocconi RP; Sullivan P; Long B; Blaize M; Brown J; Arbuckle J; Bevis K; Estes JM; Reed E; Finan MA
    Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical Outcomes and Morbidity After Radical Surgery for Ovarian Cancer in Aberdeen Royal Infirmary, the Northeast of Scotland Gynaecologic Oncology Centre.
    Kalampokas E; Young H; Bednarek A; Habib M; Parkin DE; Gurumurthy M; Cairns M
    Anticancer Res; 2018 Feb; 38(2):923-928. PubMed ID: 29374722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
    Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
    Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved Postoperative Pain Control for Cytoreductive Surgery in Women With Ovarian Cancer Using Patient-Controlled Epidural Analgesia.
    Oh TK; Lim MC; Lee Y; Yun JY; Yeon S; Park SY
    Int J Gynecol Cancer; 2016 Mar; 26(3):588-93. PubMed ID: 26825838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.